Joseph T. Curti
Director/Board Member at Morehouse School of Medicine
Joseph T. Curti active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Morehouse School of Medicine | Director/Board Member | - | - |
Career history of Joseph T. Curti
Former positions of Joseph T. Curti
| Companies | Position | Start | End |
|---|---|---|---|
Ferring Pharmaceuticals, Inc.
 Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | President | 1994-12-31 | 1997-12-31 |
| Searle Research & Development | Corporate Officer/Principal | - | - |
| BELLUS HEALTH | President | - | - |
| INTERPACE BIOSCIENCES, INC. | Director/Board Member | 2003-07-31 | - |
Training of Joseph T. Curti
| Thomas Jefferson University | Doctorate Degree |
| St. Joseph's University | Undergraduate Degree |
Statistics
International
| United States | 7 |
| Canada | 2 |
Operational
| Director/Board Member | 2 |
| President | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| INTERPACE BIOSCIENCES, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Health Technology |
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
| Searle Research & Development |
- Stock Market
- Insiders
- Joseph T. Curti
- Experience
